Moleculin to Present at the 37th Annual ROTH Conference
Moleculin Biotech (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing treatments for hard-to-treat tumors and viruses, has announced its participation in the 37th Annual ROTH Conference in Dana Point, CA.
Chairman and CEO Walter Klemp will engage in a fireside chat on Tuesday, March 18, 2025, at 11:00 AM PT. The presentation will be accessible via live webcast through the Events page in the Investors section of Moleculin's website. Management will also be available for one-on-one meetings with qualified registered conference attendees.
Moleculin Biotech (Nasdaq: MBRX), un'azienda farmaceutica in fase avanzata focalizzata sullo sviluppo di trattamenti per tumori e virus difficili da trattare, ha annunciato la sua partecipazione alla 37ª Conferenza Annuale ROTH a Dana Point, CA.
Il presidente e CEO Walter Klemp parteciperà a una conversazione informale martedì 18 marzo 2025, alle 11:00 AM PT. La presentazione sarà accessibile tramite webcast dal vivo attraverso la pagina Eventi nella sezione Investitori del sito web di Moleculin. La direzione sarà anche disponibile per incontri individuali con i partecipanti registrati qualificati alla conferenza.
Moleculin Biotech (Nasdaq: MBRX), una empresa farmacéutica en etapa avanzada centrada en el desarrollo de tratamientos para tumores y virus difíciles de tratar, ha anunciado su participación en la 37ª Conferencia Anual ROTH en Dana Point, CA.
El presidente y CEO Walter Klemp participará en una charla informal el martes 18 de marzo de 2025, a las 11:00 AM PT. La presentación será accesible a través de una transmisión en vivo en la página de Eventos en la sección de Inversores del sitio web de Moleculin. La dirección también estará disponible para reuniones individuales con los asistentes registrados calificados a la conferencia.
몰레큘린 바이오텍 (Nasdaq: MBRX), 치료하기 어려운 종양과 바이러스에 대한 치료법 개발에 집중하는 후기 단계 제약 회사가 제37회 연례 로스 컨퍼런스에 참여한다고 발표했습니다. 이는 다나 포인트, CA에서 열립니다.
회장 겸 CEO인 월터 클렘프는 2025년 3월 18일 화요일 오전 11시(PT)에 파이어사이드 채팅에 참여할 예정입니다. 발표는 몰레큘린 웹사이트의 투자자 섹션 이벤트 페이지를 통해 실시간 웹캐스트로 접근할 수 있습니다. 경영진은 또한 등록된 참석자와의 일대일 회의도 가능합니다.
Moleculin Biotech (Nasdaq: MBRX), une entreprise pharmaceutique en phase avancée axée sur le développement de traitements pour les tumeurs et virus difficiles à traiter, a annoncé sa participation à la 37e Conférence Annuelle ROTH à Dana Point, CA.
Le président et PDG Walter Klemp participera à une discussion informelle le mardi 18 mars 2025, à 11h00 PT. La présentation sera accessible par webdiffusion en direct via la page Événements dans la section Investisseurs du site Web de Moleculin. La direction sera également disponible pour des réunions individuelles avec les participants enregistrés qualifiés à la conférence.
Moleculin Biotech (Nasdaq: MBRX), ein Unternehmen der späten Phase in der Pharmaindustrie, das sich auf die Entwicklung von Behandlungen für schwer zu behandelnde Tumoren und Viren konzentriert, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz in Dana Point, CA, angekündigt.
Der Vorsitzende und CEO Walter Klemp wird am Dienstag, den 18. März 2025, um 11:00 Uhr PT an einem Feuerplatzgespräch teilnehmen. Die Präsentation wird über einen Live-Webcast auf der Veranstaltungsseite im Investorenbereich der Moleculin-Website zugänglich sein. Das Management wird auch für persönliche Gespräche mit qualifizierten registrierten Konferenzteilnehmern zur Verfügung stehen.
- None.
- None.
Live webcast fireside chat on Tuesday, March 18th at 11:00 AM PT
In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.
A live webcast of the fireside chat will be available on the Events page in the Investors section of the Company's website (moleculin.com).
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-37th-annual-roth-conference-302396372.html
SOURCE Moleculin Biotech, Inc.
FAQ
When is Moleculin (MBRX) presenting at the 2025 ROTH Conference?
How can investors watch Moleculin's (MBRX) ROTH Conference presentation?
What type of presentation will MBRX deliver at the ROTH Conference?
Will MBRX management be available for individual investor meetings at ROTH?
What is Moleculin's (MBRX) current business focus?
